India’s Actis Equity Firm Adds To Paras Ownership, Hires New CEO
This article was originally published in PharmAsia News
A private equity firm increased its control of Paras Pharmaceuticals and hired a new CEO to manage the firm. Actis now holds 60 percent of the shares in Paras, a private company, after a deal with a member of the founding Patel family, which retains 30 percent. The CEO, who was not identified, is expected to take over in two months. Principals in the two firms would not comment. (Click here for more
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.